Capital, L.P. Stonepine Net Worth

The estimated Net Worth of Capital, L.P. Stonepine is at least $10.5 Million dollars as of 27 December 2018. Capital Stonepine owns over 250,000 units of Chiasma Inc stock worth over $8,217,202 and over the last 7 years Capital sold CHMA stock worth over $2,250,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Stonepine CHMA stock SEC Form 4 insiders trading

Capital has made over 7 trades of the Chiasma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital sold 250,000 units of CHMA stock worth $750,000 on 27 December 2018.

The largest trade Capital's ever made was selling 500,000 units of Chiasma Inc stock on 26 December 2018 worth over $1,500,000. On average, Capital trades about 146,747 units every 41 days since 2017. As of 27 December 2018 Capital still owns at least 2,185,426 units of Chiasma Inc stock.

You can see the complete history of Capital Stonepine stock trades at the bottom of the page.

What's Capital Stonepine's mailing address?

Capital's mailing address filed with the SEC is 919 NW Bond St #204, Bend, OR 97701, USA.

Insiders trading at Chiasma Inc

Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke, and John F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.

What does Chiasma Inc do?

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

Complete history of Capital Stonepine stock trades at Apollo Endosurgery Inc and Chiasma Inc

Chiasma Inc executives and stock owners

Chiasma Inc executives and other stock owners filed with the SEC include:

• Raj Kannan,
  Chief Executive Officer, Director
• anand Varadan,
  Executive Vice President, Chief Commercial Officer
• Mark Fitzpatrick,
  President, Chief Financial Officer
• William Ludlam,
  Senior Vice President - Clinical Development and Medical Affairs
• Lee Giguere,
  Vice President, General Counsel, Secretary
• Drew Enamait,
  Vice President, Finance and Administration, Principal Accounting Officer
• Roni Mamluk,
  Director
• David Stack,
  Independent Chairman of the Board
• Scott Minick,
  Independent Director
• John Scarlett,
  Independent Director
• John Thero,
  Independent Director
• Todd Foley,
  Independent Director
• Bard Geesaman,
  Independent Director
• Ashley Robinson,
  IR Contact Officer
• Health Ventures Lp Wertheim...,
  
• Bio Ventures Iv Qp Lpevnin ...,
  
• Ansbert Gadicke,
  Director
• Mark Leuchtenberger,
  CEO, President
• James R Tobin,
  Director
• Tara Mc Carthy,
  General Counsel and Secretary
• Vincent J Miles,
  Director
• Llp Abingworth,
  10% owner
• John Brendan Doyle,
  Chief Financial Officer
• Capital, L.P. Stonepine,
  10% owner